BG107157A - Пелети със забавено освобождаване съдържащи ставудин - Google Patents

Пелети със забавено освобождаване съдържащи ставудин

Info

Publication number
BG107157A
BG107157A BG107157A BG10715702A BG107157A BG 107157 A BG107157 A BG 107157A BG 107157 A BG107157 A BG 107157A BG 10715702 A BG10715702 A BG 10715702A BG 107157 A BG107157 A BG 107157A
Authority
BG
Bulgaria
Prior art keywords
beadlets
stavudine
extrusion
coated
magnesium stearate
Prior art date
Application number
BG107157A
Other languages
English (en)
Inventor
Robert Abramowitz
DONOGHUE Denise O'
Nemichand JAIN
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of BG107157A publication Critical patent/BG107157A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Изобретението се отнася до форми с удължено действие на активния агент ставудин. Те включват пелети, които са образувани чрез екструзия-сферонизация,и имат изолиращо покритие. Пелетите също са покрити с модифициращо скоростта на освобождаване покритие, като твърда желатинова капсула, съдържаща такива пелети, осигурява кръвни нива на ставудин приблизително за 24 h. Пелетите са изготвени от суха смес на ставудин, един сферообразуващ агент, подходящ разредител и стабилизиращо количество магнезиевстеарат. Магнезиевият стеарат стабилизира ставудина срещу разграждане, дължащо се на хидролиза в присъствието на ограничено количество вода, необходимо за процеса на екструзия-сферонизация. Изобретението се отнася и до твърди желатинови капсули, които съдържат освен пелетите със ставудин, също и сходни пелети, включващи други терапевтични агенти, предназначени за лечение на ретровирусни инфекции.
BG107157A 2000-03-30 2002-09-30 Пелети със забавено освобождаване съдържащи ставудин BG107157A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19358800P 2000-03-30 2000-03-30
PCT/US2001/010078 WO2001074329A2 (en) 2000-03-30 2001-03-29 Sustained release beadlets containing stavudine

Publications (1)

Publication Number Publication Date
BG107157A true BG107157A (bg) 2003-06-30

Family

ID=22714247

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107157A BG107157A (bg) 2000-03-30 2002-09-30 Пелети със забавено освобождаване съдържащи ставудин

Country Status (26)

Country Link
US (1) US7135465B2 (bg)
EP (1) EP1267879A2 (bg)
JP (1) JP2003528905A (bg)
KR (1) KR20030011805A (bg)
CN (1) CN1187052C (bg)
AR (1) AR027748A1 (bg)
AU (1) AU2001249591A1 (bg)
BG (1) BG107157A (bg)
BR (1) BR0109602A (bg)
CA (1) CA2404687A1 (bg)
CZ (1) CZ20023003A3 (bg)
EE (1) EE200200564A (bg)
GE (1) GEP20043285B (bg)
HU (1) HUP0302631A2 (bg)
IL (1) IL151475A0 (bg)
LT (1) LT5045B (bg)
LV (1) LV12939B (bg)
MX (1) MXPA02009534A (bg)
NO (1) NO20024645D0 (bg)
NZ (1) NZ522250A (bg)
PE (1) PE20011179A1 (bg)
PL (1) PL366089A1 (bg)
RU (1) RU2239435C2 (bg)
SK (1) SK12822002A3 (bg)
WO (1) WO2001074329A2 (bg)
ZA (1) ZA200207760B (bg)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
AU2003257425A1 (en) * 2002-06-27 2004-01-19 Cilag Ag Spherical pellet containing a water-soluble active ingredient
CA2529984C (en) 2003-06-26 2012-09-25 Isa Odidi Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060024361A1 (en) * 2004-07-28 2006-02-02 Isa Odidi Disintegrant assisted controlled release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
CN100548309C (zh) * 2004-11-24 2009-10-14 东北制药总厂 司他夫定缓释片剂
TWI457136B (zh) 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
CA2607600A1 (en) * 2005-06-16 2006-12-28 Forest Laboratories, Inc. Modified and immediate release memantine bead formulation
ATE484284T1 (de) * 2005-08-31 2010-10-15 Cipla Ltd Pharmazeutische kombinationen mit lamivudin, stavudin und nevirapin
GB0525461D0 (en) 2005-12-15 2006-01-25 Archimedes Dev Ltd Pharmaceutical compositions
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
EP2007360B1 (en) 2006-04-03 2014-11-26 Isa Odidi Controlled release delivery device comprising an organosol coat
CA2648278C (en) * 2006-04-03 2019-05-28 Isa Odidi Drug delivery composition
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
TWI494133B (zh) 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
CN102319181B (zh) * 2011-09-08 2014-07-16 广东大华农动物保健品股份有限公司 一种微囊型动物药品的包被工艺
US20140271893A1 (en) * 2013-03-15 2014-09-18 Mcneil-Ppc, Inc. Coated phenylephrine particles and use thereof in pharmaceutical formulations
EP3169314A1 (en) * 2014-07-17 2017-05-24 Dow Global Technologies LLC Ethylcellulose dispersion and film
CN105511174A (zh) * 2016-01-05 2016-04-20 深圳市华星光电技术有限公司 液晶显示面板和显示装置

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671963A (en) 1983-10-28 1987-06-09 Germino Felix J Stearate treated food products
US4670270A (en) 1984-05-07 1987-06-02 Germino Felix J Stearate treated food products
US4940556A (en) 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
US4978655A (en) * 1986-12-17 1990-12-18 Yale University Use of 3'-deoxythymidin-2'-ene (3'deoxy-2',3'-didehydrothymidine) in treating patients infected with retroviruses
GB8707421D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
AU663146B2 (en) 1991-12-30 1995-09-28 R.P. Scherer Technologies, Inc. Microcrystalline cellulose spheronization composition
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
FI101039B (fi) 1992-10-09 1998-04-15 Eeva Kristoffersson Menetelmä lääkepellettien valmistamiseksi
US5869097A (en) * 1992-11-02 1999-02-09 Alza Corporation Method of therapy comprising an osmotic caplet
GB9403449D0 (en) 1994-02-23 1994-04-13 Wellcome Found Therapeutic benzonitriles
EP0749421B1 (en) 1994-03-07 1999-09-15 Vertex Pharmaceuticals Incorporated Sulphonamide derivatives as aspartyl protease inhibitors
US5955485A (en) 1995-02-23 1999-09-21 Janssen Pharmaceutica, N.V. Use of fused benzothiazoles as neuroprotectants
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US5691372A (en) 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
SK79998A3 (en) 1995-12-15 1999-02-11 Cryopreservation Tech Cc Composition for organ cryopreservation and treatment of viral and bacterial infections
SE9600072D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
US5883252A (en) 1996-01-26 1999-03-16 Vertex Pharmaceuticals Incorporated Aspartyl protease inhibitors
US5766623A (en) 1996-03-25 1998-06-16 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Compactable self-sealing drug delivery agents
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
US5780055A (en) 1996-09-06 1998-07-14 University Of Maryland, Baltimore Cushioning beads and tablet comprising the same capable of forming a suspension
US5905068A (en) 1996-09-24 1999-05-18 Abbott Laboratories Retroviral protease inhibiting compounds
EP0954291B1 (en) 1996-10-25 2005-12-28 Shire Laboratories Inc. Soluble form osmotic dose delivery system
US5962462A (en) 1996-12-13 1999-10-05 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US5919776A (en) 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US6124319A (en) 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
US6136827A (en) 1997-07-25 2000-10-24 Merck & Co., Inc. Cyclic amine modulations of chemokine receptor activity
ATE285226T1 (de) 1997-08-11 2005-01-15 Alza Corp Gastrische zurückhalteform zur verlängerten freisetzung eines wirkstoffs
US6166037A (en) 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
JP2002522354A (ja) * 1997-09-19 2002-07-23 シャイア ラボラトリーズ，インコーポレイテッド 固溶体ビードレット
US5904937A (en) 1997-10-03 1999-05-18 Fmc Corporation Taste masked pharmaceutical compositions
US6180634B1 (en) 1997-11-13 2001-01-30 Merck & Co., Inc. Combination therapy for the treatment of AIDS
US6013644A (en) 1997-12-12 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US6172061B1 (en) 1997-12-19 2001-01-09 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative
US6140349A (en) 1998-02-02 2000-10-31 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
US6093743A (en) 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US6194391B1 (en) 1998-06-24 2001-02-27 Emory University 3′-azido-2′,3′-dideoxyuridine administration to treat HIV and related test protocol
WO2000057870A2 (en) 1999-03-31 2000-10-05 The Procter & Gamble Company Viral treatment
US6136835A (en) 1999-05-17 2000-10-24 The Procter & Gamble Company Methods of treatment for viral infections

Also Published As

Publication number Publication date
LT2002099A (en) 2003-04-25
NO20024645L (no) 2002-09-27
CN1187052C (zh) 2005-02-02
ZA200207760B (en) 2004-01-30
LV12939B (en) 2003-04-20
MXPA02009534A (es) 2003-05-14
KR20030011805A (ko) 2003-02-11
WO2001074329A2 (en) 2001-10-11
NO20024645D0 (no) 2002-09-27
NZ522250A (en) 2004-09-24
CA2404687A1 (en) 2001-10-11
RU2239435C2 (ru) 2004-11-10
CN1420774A (zh) 2003-05-28
IL151475A0 (en) 2003-04-10
US20020002147A1 (en) 2002-01-03
BR0109602A (pt) 2004-06-29
RU2002126540A (ru) 2004-03-27
WO2001074329A3 (en) 2002-05-10
CZ20023003A3 (cs) 2002-11-13
EE200200564A (et) 2004-06-15
LT5045B (lt) 2003-08-25
AU2001249591A1 (en) 2001-10-15
EP1267879A2 (en) 2003-01-02
JP2003528905A (ja) 2003-09-30
SK12822002A3 (sk) 2003-02-04
PE20011179A1 (es) 2001-12-06
HUP0302631A2 (hu) 2003-11-28
PL366089A1 (en) 2005-01-24
AR027748A1 (es) 2003-04-09
GEP20043285B (en) 2004-07-26
US7135465B2 (en) 2006-11-14

Similar Documents

Publication Publication Date Title
BG107157A (bg) Пелети със забавено освобождаване съдържащи ставудин
HK1060045A1 (en) Formulations comprising ibuprofen and diphenhydramine and the use thereof for the treatment of sleepdisturbances
NO20092274L (no) Ansamycinformuleringer og fremgangsmater for anvendelse derav
RS56252B1 (sr) Jednodnevne formulacije oksikodona
MY137348A (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
TW200624431A (en) Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
BR0310006A (pt) Derivados de 5-tio-beta-d-glicopiranosìdeo de arila e agentes terapêuticos para diabetes contendo os mesmos
TNSN07145A1 (fr) Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
BR0212787A (pt) Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica
BR0207316A (pt) Derivados de epotilona para o tratamento de tumores refratários
WO2007002836A3 (en) Methods and compositions for the prevention and treatment of kidney disease
PL374443A1 (en) Novel pyrimidineamide derivatives and the use thereof
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
EP0870502A3 (en) Use of adenosine uptake inhibitors for the manufacture of a medicament for the treatment of pancreatitis
MX2008011769A (es) Derivados de ftalazinona pirazol, su fabricacion y uso como agentes farmaceuticos.
HUP0001104A2 (hu) Ibuprofent és domperidont tartalmazó készítmények migrén kezelésére
BR0114276A (pt) Derivados de benzodiazepina ou sais destes farmaceuticamente aceitáveis, agente para inibir o fator x de coagulação do sangue ativado, composição farmacêutica, e, inibidor da coagulação sanguìnea ou um agente para prevenir ou tratar a trombose ou o embolismo
HUP0102987A2 (hu) Hatóanyagként asztrocita funkciójavító szert tartalmazó készítmény Parkinson-kór kezelésére
TW200720239A (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents
TW200736220A (en) Pyridylsulfonamide derivatives, their manufacture and use as pharmaceutical agents
TW200612914A (en) Novel oxidized thioether derivatives, their manufacture and use as pharmaceutical agents
MXPA05010135A (es) Nuevos derivados de oxazol, procedimiento para su fabricacion y uso como agentes farmaceuticos.
TW200602329A (en) Novel diazine derivatives, their manufacture and use as pharmaceutical agents
TW200626149A (en) Tricycles, their manufacture and use as pharmaceutical agents